OS Therapies Inc 10-K — AI Bull & Bear Analysis

The investment case for OS Therapies is a high-stakes trade-off between extraordinary clinical potential and imminent financial collapse. The company has successfully proven the biological efficacy of OST-HER2, but it is currently operating on a 'hand-to-mouth' basis, with a balance sheet that triggers a going concern warning from its auditors. The window for success depends entirely on the company's ability to secure a massive capital infusion before the Q2 2026 BLA submission. Ultimately, the filing reveals a company that is technically proficient in science but struggling with financial discipline. If the FDA accepts the Phase IIb data for accelerated approval, the stock could re-rate violently upward. However, if the agency demands a randomized trial or if the company fails to secure more funding, the current capital deficiency and high burn rate make a total loss a distinct possibility.